Table 2.

White blood cell subsets in patients with metastatic colorectal cancer 2 months after treatment with cetuximab-based regimens and in healthy controls.

	Patients with mCRC	Patients with mCRC (responders)	Patients with mCRC (non-responders)	Healthy controls (13)
n	33	30	3	41
% CD16+ lymphocytes	14.84 ± 9.14*	14.08 ± 9.24**	22.44 ± 2.27	19.08 ± 7.20
% CD16+ lymphocytes in the overall white blood cells	2.76 ± 2.72	2.80 ± 2.86	2.39 ± 0.41	2.92 ± 1.45
% CD56+ lymphocytes	7.50 ± 7.26*	6.73 ± 6.42**	15.21 ± 12.16	15.00 ± 8.58
% CD56+ lymphocytes in the overall white blood cells	1.28 ± 1.54*	1.25 ± 1.57**	1.60 ± 1.38	2.53 ± 2.28
n	37	34	3	41
% CD16+CD56+ lymphocytes	5.58 ± 6.05*	5.06 ± 5.68**	11.40 ± 8.47	10.87 ± 6.44
% CD16+CD56+ lymphocytes in the overall white blood cells	0.89 ± 1.06*	0.86 ± 1.08**	1.18 ± 0.95	1.81 ± 1.47
n	39	36	3	41
% lymphocytes	18.47 ± 12.70	19.27 ± 12.90	8.87 ± 0.75**	20.39 ± 8.53
% granulocytes	68.47 ± 15.65	67.37 ± 15.80	81.71 ± 1.67	68.90 ± 10.63
% granulocytes/% lymphocytes	5.85 ± 4.29	5.57 ± 4.35	9.26 ± 0.90**	4.20 ± 2.23

The numbers represent mean ± SD.

*p < 0.05 when compared with healthy controls (Mann–Whitney U-test).

**p < 0.0167 when compared with healthy controls (Mann–Whitney U-test).